Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

Orca-T improves AML survival in phase Ib trial subgroup

Orca Bio will present new data at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago.

May 24, 2024

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.

May 24, 2024

Clinical Roundup

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.

May 17, 2024

Vol.50 No.20

In Brief

Damian Green named chief of Division of Transplantation & Cellular Therapy at Sylvester

Damian Green will join Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine this spring to lead its transplantation and cellular therapy services. Green was named chief of the Division of Transplantation & Cellular Therapy, as well as assistant director of Translational Research, beginning March 1.

February 23, 2024

Vol.50 No.08

Drugs & Targets

Tempus develops MRD assay for colorectal cancer

Tempus has added a novel MRD assay, xM, to its testing solutions.

January 26, 2024

Vol.50 No.04

Clinical Roundup

UNM completes the first allogeneic stem cell transplant in the state

Doctors at the University of New Mexico Comprehensive Cancer Center successfully treated blood cancer patients using allogeneic stem cell transplant—a first for New Mexico.

January 19, 2024

Vol.50 No.03

Lower MRD prior to HCT associated with better outcomes in FLT3-ITD AML

YOU MAY BE INTERESTED IN

Orca-T improves AML survival in phase Ib trial subgroup

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Damian Green named chief of Division of Transplantation & Cellular Therapy at Sylvester

Tempus develops MRD assay for colorectal cancer

UNM completes the first allogeneic stem cell transplant in the state

Renew today!

Subscriber content

Login